The CDC reportedly set aside $1.6 million for a suspended hepatitis B vaccine trial in Guinea‑Bissau, drawing criticism over ethics and budget priorities.
The CDC reportedly set aside $1.6 million for a suspended hepatitis B vaccine trial in Guinea‑Bissau, drawing criticism over ethics and budget priorities.